• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch .

作者信息

Chheda Zinal S, Mueller Sabine, Hegde Bindu, Yamamichi Akane, Butterfield Lisa H, Okada Hideho

机构信息

Sanofi Genzyme, Cambridge, Massachusetts, USA.

Department of Neurology, UCSF, San Francisco, California, USA.

出版信息

J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006617.

DOI:10.1136/jitc-2022-006617
PMID:36944450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10032395/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e517/10032395/aa56abf83e94/jitc-2022-006617f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e517/10032395/aa56abf83e94/jitc-2022-006617f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e517/10032395/aa56abf83e94/jitc-2022-006617f01.jpg

相似文献

1
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch .关于Immisch所著的《H3.3K27M突变并非HLA - A2 +弥漫性中线胶质瘤患者免疫治疗的合适靶点》的通信
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006617.
2
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda .对Chheda的《关于“H3.3K27M突变并非HLA - A2阳性弥漫性中线胶质瘤患者免疫治疗合适靶点”的通信》的回复
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2023-006784.
3
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2 patients with diffuse midline glioma.H3.3K27M 突变不是 HLA-A2 型弥漫性中线胶质瘤患者免疫治疗的合适靶点。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005535.
4
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.新型和共享的组蛋白 3 变体 H3.3K27M 突变衍生的神经抗原用于胶质细胞瘤 T 细胞治疗。
J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.
5
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.质谱细胞术检测弥漫性中线胶质瘤中 H3.3K27M 特异性疫苗反应。
J Clin Invest. 2020 Dec 1;130(12):6325-6337. doi: 10.1172/JCI140378.
6
Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.组蛋白 H3.3K27M 在小儿神经胶质瘤中动员多种癌/睾丸（CT）抗原。
Mol Cancer Res. 2018 Apr;16(4):623-633. doi: 10.1158/1541-7786.MCR-17-0460. Epub 2018 Feb 16.
7
Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.检测弥漫性中线胶质瘤患儿脑脊液来源肿瘤 DNA 中的组蛋白 H3 突变。
Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.
8
Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.局限于HLA-A∗02:01的内源性H3.3K27M衍生肽不足以在弥漫性中线胶质瘤中进行免疫靶向。
Mol Ther Oncolytics. 2023 Aug 15;30:167-180. doi: 10.1016/j.omto.2023.08.005. eCollection 2023 Sep 21.
9
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.组蛋白 H3.3K27M 突变在小儿神经胶质瘤中重塑 H3K27 甲基化和基因表达。
Genes Dev. 2013 May 1;27(9):985-90. doi: 10.1101/gad.217778.113. Epub 2013 Apr 19.
10
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.影像学诊断的中线胶质瘤中 H3 K27M 突变的发生率及临床病理特征。
J Neurooncol. 2019 May;143(1):87-93. doi: 10.1007/s11060-019-03134-x. Epub 2019 Mar 12.

引用本文的文献

1
Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.局限于HLA-A∗02:01的内源性H3.3K27M衍生肽不足以在弥漫性中线胶质瘤中进行免疫靶向。
Mol Ther Oncolytics. 2023 Aug 15;30:167-180. doi: 10.1016/j.omto.2023.08.005. eCollection 2023 Sep 21.

本文引用的文献

1
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2 patients with diffuse midline glioma.H3.3K27M 突变不是 HLA-A2 型弥漫性中线胶质瘤患者免疫治疗的合适靶点。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005535.
2
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.质谱细胞术检测弥漫性中线胶质瘤中 H3.3K27M 特异性疫苗反应。
J Clin Invest. 2020 Dec 1;130(12):6325-6337. doi: 10.1172/JCI140378.
3
Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
弥漫性内生性桥脑胶质瘤的非炎症性肿瘤微环境。
Acta Neuropathol Commun. 2018 Jun 28;6(1):51. doi: 10.1186/s40478-018-0553-x.
4
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.新型和共享的组蛋白 3 变体 H3.3K27M 突变衍生的神经抗原用于胶质细胞瘤 T 细胞治疗。
J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.
5
K27M-mutant histone-3 as a novel target for glioma immunotherapy.K27M突变型组蛋白-3作为神经胶质瘤免疫治疗的新靶点。
Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017.